Immunologic monitoring during combined radiochemoimmunotherapy in inoperable lung cancer

Ercole Sega, Massimo Rinaldi, Marcella Mottolese, Paola Cordiali-Fei, M. Cinzia Apollonj, Maurizio de Santis, Tommaso Gionfra, Alessandro Casali, Antonio Gianciotta, Corrado Gallo-Curcio

Research output: Contribution to journalArticlepeer-review


49 patients with advanced lung cancer underwent a combined treatment including radiochemoim-munotherapy. Before and at the end of the combined treatment, the immune status of the patients has been evaluated by testing the immunoreactivity to PPD in vivo and the phytohemagglutinin lymphocyte response and the rosette-forming cells in vitro. While the in vitro tests were not significantly modified by immunostimulation, as regards the immunoreactivity to PPD, we observed a positive conversion at the end of the treatment in 11 out of 25 patients who showed a negative reaction before therapy. All the patients who converted from negative to positive showed also a good response to therapy with regression or no progression of the tumor. Survival curves confirmed the prognostic value of PPD reactivity.

Original languageEnglish
Pages (from-to)390-396
Number of pages7
Issue number6
Publication statusPublished - 1980


  • Cell-mediated immunity in vivo and in vitro
  • Immunotherapy
  • Lung cancer
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Immunologic monitoring during combined radiochemoimmunotherapy in inoperable lung cancer'. Together they form a unique fingerprint.

Cite this